Home LiteratureArticle Details
PMID: 19837671 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

The Journal of biological chemistry ·Vol. 284 ·No. 50 ·2009-12-11 ·Pages 35060-72

Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, Tanaka Y, Sata T, Tokunaga K

Abstract

Bone marrow stromal antigen 2 (BST-2, also known as tetherin) is a recently identified interferon-inducible host restriction factor that can block the production of enveloped viruses by trapping virus particles at the cell surface. This antiviral effect is counteracted by the human immunodeficiency virus type 1 (HIV-1) accessory protein viral protein U (Vpu). Here we show that HIV-1 Vpu physically interacts with BST-2 through their mutual transmembrane domains and leads to the degradation of this host factor via a lysosomal, not proteasomal, pathway. The degradation is partially controlled by a cellular protein, beta-transducin repeat-containing protein (betaTrCP), which is known to be required for the Vpu-induced degradation of CD4. Importantly, targeting of BST-2 by Vpu occurs at the plasma membrane followed by the active internalization of this host protein by Vpu independently of constitutive endocytosis. Thus, the primary site of action of Vpu is the plasma membrane, where Vpu targets and internalizes cell-surface BST-2 through transmembrane interactions, leading to lysosomal degradation, partially in a betaTrCP-dependent manner. Also, we propose the following configuration of BST-2 in tethering virions to the cell surface; each of the dimerized BST-2 molecules acts as a bridge between viral and cell membranes.

MeSH Terms
Animals Antigens, CD/genetics,metabolism CD4 Antigens/metabolism Cell Line Cell Membrane/metabolism Endocytosis/physiology GPI-Linked Proteins HIV-1/genetics,metabolism Human Immunodeficiency Virus Proteins/genetics,metabolism Humans Lysosomes/metabolism Membrane Glycoproteins/genetics,metabolism Viral Regulatory and Accessory Proteins/genetics,metabolism Virion/metabolism Virus Internalization beta-Transducin Repeat-Containing Proteins/genetics,metabolism
Chemicals
Antigens, CD BST2 protein, human CD4 Antigens GPI-Linked Proteins Human Immunodeficiency Virus Proteins Membrane Glycoproteins Viral Regulatory and Accessory Proteins beta-Transducin Repeat-Containing Proteins vpu protein, Human immunodeficiency virus 1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Iwabu Yukie
Department of Pathology, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
Fujita Hideaki
Kinomoto Masanobu
Kaneko Keiko
Ishizaka Yukihito
Tanaka Yoshitaka
Sata Tetsutaro
Tokunaga Kenzo
References (64)
64 references, click to expand
  1. Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors.
    J Gen Virol. 1997 Mar;78 ( Pt 3):619-25 PMID: 9049413
  2. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.
    EMBO J. 1997 Aug 1;16(15):4531-9 PMID: 9303297
  3. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.
    J Virol. 1996 Feb;70(2):809-19 PMID: 8551619
  4. A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif.
    Mol Cell. 1998 Mar;1(4):565-74 PMID: 9660940
  5. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor.
    EMBO J. 2003 Oct 15;22(20):5480-90 PMID: 14532120
  6. CAML is required for efficient EGF receptor recycling.
    Dev Cell. 2003 Aug;5(2):245-56 PMID: 12919676
  7. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.
    J Virol. 2000 Apr;74(7):3264-72 PMID: 10708443
  8. Mutational analysis of the human immunodeficiency virus type 1 Vpu transmembrane domain that promotes the enhanced release of virus-like particles from the plasma membrane of mammalian cells.
    J Virol. 1998 Feb;72(2):1270-9 PMID: 9445027
  9. The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif.
    J Mol Biol. 1994 Feb 11;236(1):16-25 PMID: 8107101
  10. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
    PLoS Pathog. 2009 May;5(5):e1000450 PMID: 19478868
  11. Inhibition of Lassa and Marburg virus production by tetherin.
    J Virol. 2009 Mar;83(5):2382-5 PMID: 19091864
  12. Genetic organization of a chimpanzee lentivirus related to HIV-1.
    Nature. 1990 May 24;345(6273):356-9 PMID: 2188136
  13. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.
    Traffic. 2003 Oct;4(10):694-709 PMID: 12956872
  14. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Cell Host Microbe. 2008 Apr 17;3(4):245-52 PMID: 18342597
  15. Caveosomes and endocytosis of lipid rafts.
    J Cell Sci. 2003 Dec 1;116(Pt 23):4707-14 PMID: 14600257
  16. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.
    J Biol Chem. 2009 Jun 5;284(23):15927-41 PMID: 19359243
  17. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  18. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses.
    Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7381-5 PMID: 8346259
  19. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
    PLoS Pathog. 2009 Feb;5(2):e1000300 PMID: 19214216
  20. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
    J Virol. 2009 Aug;83(15):7536-46 PMID: 19474106
  21. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference.
    J Virol. 2003 Aug;77(16):8957-61 PMID: 12885912
  22. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein.
    J Virol. 1993 Aug;67(8):5056-61 PMID: 8331740
  23. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4.
    J Virol. 1992 Dec;66(12):7193-200 PMID: 1433512
  24. Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jan 1;8(1):10-22 PMID: 8548340
  25. Efficient selection for high-expression transfectants with a novel eukaryotic vector.
    Gene. 1991 Dec 15;108(2):193-9 PMID: 1660837
  26. Human immunodeficiency virus type 1 Vpu protein regulates the formation of intracellular gp160-CD4 complexes.
    J Virol. 1992 Jan;66(1):226-34 PMID: 1727486
  27. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway.
    J Virol. 1998 Mar;72(3):2280-8 PMID: 9499087
  28. Characterization of a novel simian immunodeficiency virus (SIVmonNG1) genome sequence from a mona monkey (Cercopithecus mona).
    J Virol. 2003 Jun;77(12):6879-88 PMID: 12768007
  29. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy.
    Oncogene. 2004 Nov 11;23(53):8649-58 PMID: 15467759
  30. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.
    J Virol. 1989 Sep;63(9):3784-91 PMID: 2788224
  31. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.
    Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15154-9 PMID: 14657387
  32. Cell type-dependence for Vpu function.
    J Med Primatol. 1994 Feb-May;23(2-3):146-50 PMID: 7966229
  33. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.
    Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2886-91 PMID: 19179289
  34. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth.
    Genomics. 1995 Apr 10;26(3):527-34 PMID: 7607676
  35. Influenza viruses select ordered lipid domains during budding from the plasma membrane.
    J Biol Chem. 1999 Jan 22;274(4):2038-44 PMID: 9890962
  36. Identification of a protein encoded by the vpu gene of HIV-1.
    Nature. 1988 Aug 11;334(6182):532-4 PMID: 3043230
  37. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
    Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62 PMID: 11087859
  38. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.
    PLoS Pathog. 2006 May;2(5):e39 PMID: 16699598
  39. SIVcpz in wild chimpanzees.
    Science. 2002 Jan 18;295(5554):465 PMID: 11799233
  40. Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor.
    J Virol. 2005 May;79(10):5996-6004 PMID: 15857986
  41. Primary structure of human transferrin receptor deduced from the mRNA sequence.
    Nature. 1984 Oct 18-24;311(5987):675-8 PMID: 6090955
  42. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    J Virol. 2009 Aug;83(16):7931-47 PMID: 19515779
  43. Plasma membrane rafts play a critical role in HIV-1 assembly and release.
    Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13925-30 PMID: 11717449
  44. Silencing of both beta-TrCP1 and HOS (beta-TrCP2) is required to suppress human immunodeficiency virus type 1 Vpu-mediated CD4 down-modulation.
    J Virol. 2007 Feb;81(3):1502-5 PMID: 17121803
  45. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.
    J Virol. 2009 Feb;83(4):1837-44 PMID: 19036818
  46. Cell surface CD4 interferes with the infectivity of HIV-1 particles released from T cells.
    J Biol Chem. 2002 Jan 18;277(3):1770-9 PMID: 11704677
  47. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.
    J Virol. 2001 Aug;75(15):6776-85 PMID: 11435556
  48. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Nature. 2008 Jan 24;451(7177):425-30 PMID: 18200009
  49. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
    Cell Host Microbe. 2007 Sep 13;2(3):193-203 PMID: 18005734
  50. Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.
    J Virol. 2002 Aug;76(16):8298-309 PMID: 12134035
  51. The effect of vpu on HIV-1-induced syncytia formation.
    J Acquir Immune Defic Syndr (1988). 1993 Feb;6(2):135-41 PMID: 8094456
  52. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
    Cell Host Microbe. 2009 Mar 19;5(3):285-97 PMID: 19286137
  53. Clathrin-coated pits: vive la différence?
    Traffic. 2007 Aug;8(8):970-82 PMID: 17547704
  54. A novel membrane antigen selectively expressed on terminally differentiated human B cells.
    Blood. 1994 Sep 15;84(6):1922-30 PMID: 8080996
  55. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif.
    J Cell Sci. 2007 Nov 1;120(Pt 21):3850-8 PMID: 17940069
  56. Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.
    Nat Med. 2008 Jun;14(6):641-7 PMID: 18500349
  57. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    PLoS Pathog. 2009 May;5(5):e1000443 PMID: 19461879
  58. A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells.
    J Cell Biol. 2009 Mar 9;184(5):721-36 PMID: 19273615
  59. A novel gene of HIV-1, vpu, and its 16-kilodalton product.
    Science. 1988 Sep 2;241(4870):1221-3 PMID: 3261888
  60. The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.
    J Virol. 1990 Feb;64(2):621-9 PMID: 2404139
  61. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
    Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73 PMID: 19196977
  62. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
    Biochem Biophys Res Commun. 1999 May 19;258(3):583-91 PMID: 10329429
  63. Function of human immunodeficiency virus type 1 Vpu protein in various cell types.
    J Gen Virol. 1995 Nov;76 ( Pt 11):2717-22 PMID: 7595378
  64. Envelope glycoprotein and CD4 independence of vpu-facilitated human immunodeficiency virus type 1 capsid export.
    J Virol. 1992 Aug;66(8):5119-26 PMID: 1629967
Article Info
Journal
The Journal of biological chemistry
Abbr.
J Biol Chem
ISSN
1083-351X
Published
2009-12-11
Epub
2009-00-16
Pages
35060-72
Language
English
Region
United States
NLM ID
2985121R
PMCID
PMC2787367
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]